PAP
TENX icon

Persistent Asset Partners’s Tenax Therapeutics TENX Stock Holding History

Persistent Asset Partners’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,182
Closed -$743K – 905
2026
Q1 		$930K Sell
58,182
-7,090
-11% -$95.9K 0.35% 70
2025
Q4 		$796K Buy
+65,272
New +$568K 0.36% 77

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Persistent Asset Partners's TENX Position: Q2 2026 in Review

Persistent Asset Partners sold out of Tenax Therapeutics (TENX) in Q2 2026, closing a stake of 58,182 shares — an estimated $743K sold.

Persistent Asset Partners first reported a position in TENX in Q4 2025 and held it in 2 quarters. The position peaked at $930K in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Persistent Asset Partners reported no remaining Tenax Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 58,182 Tenax Therapeutics shares in Q2 2026, an estimated $743K.
  • Persistent Asset Partners first reported a position in Tenax Therapeutics in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Tenax Therapeutics position peaked at $930K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.